Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Chemotherapy, Isotretinoin, and Interferon Alfa in Untreated AML
NCT00003405Phase 2Withdrawn
- Sponsor
- Rush University Medical Center
- Start
- Apr 1998
- Primary completion
- Apr 1999
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amifostine, isotretinoin, interferon alfa in acute myeloid leukemia (AML), sponsored by Rush University Medical Center. Planned start Apr 1998; status: withdrawn.
02
Drugs
amifostineisotretinoininterferon alfa
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003405.